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420Objective: To evaluate paracorporeal lung assist devices to treat neonates and children with decompensated
respiratory failure as a bridge to recovery or lung transplantation.
Methods: One neonate (23 days old) and 3 young children (aged 2, 9, and 23 months) presented with primary
lung disease with pulmonary hypertension, including alveolar capillary dysplasia in 2 and right pulmonary
hypoplasia and primary pulmonary hypertension in 1. The patients were listed for lung transplantation but
decompensated and required extracorporeal membrane oxygenation (ECMO). The patients were transitioned
from ECMO to a pumpless paracorporeal lung assist device (Maquet Quadrox-iD oxygenator in 3, Novalung
in 1) with inflow from the pulmonary artery and return to the left atrium.
Results: The patientswereweaned fromECMOand supported by the device for 44 29 days (range, 5-74). Three
patients were extubated while supported by the device (after 9, 15, and 72 days). One patient was bridged to lung
transplant (9months old, with alveolar capillary dysplasia, supported 5 days). One patient was bridged to recovery
with maximal medical therapy (23 months old, with primary pulmonary hypertension, supported 23 days). Two
patients died while awaiting a suitable lung donor after a support time of 54 and 72 days.
Conclusions: Pediatric patients bridged from ECMO to lung transplantation have poor results. An alternative
method for longer term respiratory support was necessary as a bridge for these patients. The use of a
paracorporeal lung assist device successfully supported 4 patients to recovery, lung transplantation, or past
the average wait time for pediatric donor lungs (27 days). This therapy has the potential to bridge children
with decompensated respiratory failure to lung transplantation. (J Thorac Cardiovasc Surg 2014;147:420-7)Neonates or small children with end-stage lung disease who
develop respiratory failure requiring extracorporeal
membrane oxygenation (ECMO) have few clinical options.
Some of these patients can be weaned from ECMO,
especially if their condition can be managed with optimized
medical therapy. This, however, is an uncommon scenario,
and survival for these patients has been<50% and has often
been accompanied by significant complications.1 Although
these children can be listed for lung transplantation (LT),
the post-transplant results for patients receiving ECMO,
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The Journal of Thoracic and Cardiovascular Surgpoor outcomes, our philosophy has been to reconsider the
candidacy of listed patients if their clinical deterioration
has warranted ECMO support. This clinical conundrum
led us to seek alternative options for support, as a bridge
to lung transplantation or recovery, in listed patients with
clinical decompensation.
Recently, adult patients with end-stage respiratory failure
and pulmonary hypertension who have become decompen-
sated and required ECMO have been successfully bridged
to lung transplantation with the support of the Novalung
oxygenator (Novalung GmbH, Heilbronn, Germany) using
central cannulation with blood inflow from the pulmonary
artery (PA) and blood return to the left atrium (LA).3-5
Many of these patients have been extubated and
participated in physical therapy during support.
The present report summarizes our experience with the
first series of infants and children with severe respiratory
failure who were supported with a centrally placed
paracorporeal pumpless oxygenator in a PA to LA config-
uration. Each of these patients had pulmonary hyperten-
sion and preserved right ventricular function. These
prerequisites were intentionally chosen, because of the
presumption that the elevated pulmonary vascular resis-
tance would result in shunting blood flow through the
lower resistance paracorporeal oxygenator. All patients
were initially treated with an intent of a bridge to lung
transplantation.ery c January 2014
Abbreviations and Acronyms
ACD ¼ alveolar capillary dysplasia
ATIII ¼ antithrombin III
AV ¼ atrioventricular
ECMO ¼ extracorporeal membrane oxygenation
LA ¼ left atrium
LT ¼ lung transplantation
PA ¼ pulmonary artery
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Patient Presentation
One neonate (aged 23 days) and 3 young children (aged 2, 9, and
23 months) presented with primary lung disease, including alveolar
capillary dysplasia (ACD) in 2, horseshoe lung with right pulmonary
hypoplasia, pulmonary interstitial glycogenosis, and an atrioventricular
(AV) canal defect in 1, and primary pulmonary hypertension in 1. All these
patients had pulmonary hypertension demonstrated by echocardiography.
All patients had been evaluated and listed for LT at their clinical
deterioration requiring venoarterial ECMO support despite maximal
medical therapy. These patients were considered for paracorporeal
oxygenator support with central cannulation. Each case was reviewed
with the university human research protection office and our institutional
multidisciplinary ethics team, and extensive and open discussions were
had with each family, who agreed to proceed.
Technique of Implanting Paracorporeal Oxygenator
With Central Cannulation
Each patient was in the intensive care unit receiving ECMO support
with right carotid artery and right internal jugular venous cannulation
before being brought to the operating room. Of the 4 patients, 3 were
transitioned to traditional cardiopulmonary bypass by way of a median
sternotomy. The 23-month-old patient was transitioned directly from
ECMO to the paracorporeal Novalung support. For PA cannulation, an
aortic Berlin Heart cannula (Berlin Heart AG, Berlin, Germany) was
sewn to the main PA. The 6-mm version of the cannula was used in the 3
infants and the 9-mm version in the 23-month-old child. In 2 patients, an
interposed short piece of 8-mm Gore-Tex shunt (W. L. Gore & Associates,
Flagstaff, Ariz) was used between the 6-mm cannula and the PA (with a
pericardial washer on the Gore-Tex graft) to allow for easier implantation
and to improve the hemostasis of the cannula to PA anastomosis. For
the LA shunt, in the first 3 patients, a metal tip right angle cannula
(DLP Medtronics Inc, Grand Rapids, Mich) was inserted into the LA
through a pursestring suture (16F in the 23 day old neonate and
2-month-old infant and 22F in the 23-month-old child). After observations
of significant thrombus formation around and inside the metal cannula tip
from the first few cases, 1 of us (P.E.) devised an alternative approach for
the LA cannulation (Figure 1). This technique was used in the fourth
patient, a 9-month-old infant with ACD. LA cannulation was performed
using a 6-mm Berlin arterial cannula modified with a 10-mm-diameter
Gore-Tex graft extension. The 10-mm graft attached to the Berlin cannula
was anastomosed to a surgically created atrial septal defect (corresponding
to the area of a Blalock-Hanlon incision) by way of a right atriotomy. The
right atrial incisionwas then closed around the 10-mm shunt. In all patients,
the cannulas were passed through the chest wall, and the oxygenator was
positioned just below the patient’s feet, supported by a custom holding
device. The patient with the AV canal underwent complete repair of the
AV canal during the same operation as the transition to paracorporeal
oxygenator support.
For the 23-month-old child, who was the first to be treated,1 the
Novalung oxygenator was used to support the patient. However, theThe Journal of Thoracic and Caminimum recommended flow of the Novalung (500 mL/min) was greater
than the expected blood flow through the device for the neonate and infants.
Therefore, for the infants, the Quadrox iD oxygenator (Maquet, Wayne,
NJ), with aminimum recommended flow of 200mL/min, was used. Similar
to the Novalung, the Quadrox iD was designed to have a low gradient
across the oxygenator. A low-flow air-oxygen mixer (Sechrist Industries,
Inc, Anaheim, Calif) was used to control the sweep and inspired oxygen
percentage in the oxygenator. Blood flow through the oxygenator was
monitored continuously at the bedside using a Transonic HT110 flowmeter
(Transonic Systems, Inc, Ithaca, NY). Pressures proximal and distal to the
oxygenator were continuously monitored in the postoperative period.
Anticoagulation Management of Paracorporeal
Oxygenator
Anticoagulation was achieved using a heparin infusion with a targeted
activated clotting time of 160 to 200 seconds in 3 patients, consistent
with what has been reported for adults who have been treated with the
paracorporeal Novalung with central cannulation.5,6 In the neonatal
patient, a target activated clotting time of 180 to 220 seconds was
achieved, and aspirin was also given, as has been reported for adult
Novalung patients.7 The neonate and 2 infants also had their antithrombin
III (ATIII) levels monitored. ATIII was replaced with recombinate
ATIII (Atryn, ABO Pharmaceuticals, San Diego, Calif) to maintain
levels>80%. The circuit, including cannulas, tubing, connectors, and
oxygenator, was monitored for thrombus buildup by visual inspection
and continuous measurement of the transmembrane gradient and
postmembrane blood gases. An increase in the transmembrane gradient
of the oxygenator greater than the baseline suggested potential thrombus
buildup in the oxygenator. If that occurred, the oxygenator and connectors
were changed out at the bedside, with a circuit clamp times of<1 minute.RESULTS
These 4 patients were supported by ECMO for a period of
8 7 days. During the operation to transition to oxygenator
support, adequate flow through the oxygenator allowed
prompt weaning of cardiopulmonary bypass or ECMO
(in the Novalung patient). The duration of oxygenator
support was 44  29 days (range, 5-74). The patients and
support times on the paracorporeal oxygenator are listed
in Table 1. One patient (9 months old, with ACD, supported
for 5 days) was bridged to lung transplantation and was
doing well 10 months after transplantation. One patient
(23 months old) had primary pulmonary hypertension
and was supported on the device while the pulmonary
vasodilators were escalated. After 22 days of oxygenator
support, the patient developed an embolic stroke and
was taken to the operating room, where the Novalung
oxygenator was successfully weaned. The patient has
continued to receive an intravenous pulmonary vasodilator
and was doing well at home 34 months after weaning from
the paracorporeal oxygenator support, with minimal
neurologic sequelae from his stroke. Two patients died
while awaiting a suitable lung donor after a paracorporeal
oxygenator support time of 54 and 74 days. The neonatal
patient with ACD was supported for 54 days and was
extubated after 15 days of support.8 However, that patient
experienced a hemorrhagic stroke after 44 days of
support that progressed during the next 10 days despiterdiovascular Surgery c Volume 147, Number 1 421
FIGURE 1. Diagram demonstrating the cannulation of the left atrium for the fourth patient treated with paracorporeal oxygenator support. A 10-mm
Gore-Tex graft extension was added to a 6-mm Berlin cannula. The Gore-Tex graft was passed through the right atrium and sewn to the interatrial septum.
MPA, Main pulmonary artery; PTFE, polytetrafluoroethylene.
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taken off the LT waiting list, transitioned to comfort care,
and died. The 2-month-old infant with the AV canal defect
was supported for 72 days and experienced a small
hemorrhagic stroke after 17 days of support, but this did
not progress. The patient’s course was complicated by
need to return to the operating room for treatment of a
residual atrial septal defect, resulting in significant left to
right shunting, in part from small left-sided structures
and elevated left ventricular end-diastolic pressure that
were appreciated subsequently. This patient eventually
developed renal failure during oxygenator support. The
patient was taken off the lung transplant waiting list, and
the family decided to transition to comfort care. The patient
was extubated on postoperative day 72 and died on
postoperative day 74.
All these patients had pulmonary hypertension with
suprasystemic PA pressures (mean systolic pulmonary
pressure, 98  21 mm Hg). With the low resistance of the
oxygenator circuit and elevated pulmonary vascularTABLE 1. Overview of patient diagnoses, support times, and outcome
Age Diagnosis ECMO support (d) Lung device
23 d ACD 5 54
2 mo AV canal, R lung hypoplasia 0.1 74
9 mo ACD 9 5
23 mo PPH 17 42
ECMO, Extracorporeal membrane oxygenation; ACD, alveolar capillary dysplasia; AV, ar
422 The Journal of Thoracic and Cardiovascular Surgresistance in these patients, the flow through the circuit
was substantial in all patients. The resistance of the
oxygenator circuit was lower than the pulmonary vascular
resistance, as evidenced by the measured preoxygenator
pressures during device support were lower than the
preoperative right ventricle pressures (Table 2). We
measured a pressure decrease across the Quadrox iD
oxygenator, with a range from 6 to 14 mm Hg at a flow of
324 to 884 mL/min. The flow and the mean preoxygenator
pressure for the neonate and 9-month-old patient supported
with the Quadrox are shown in Figure 2. Overall, the flow
remained within a narrow range for most of the treatment
duration.
The balance of blood flow through the oxygenator circuit
and the native lungs cannot be directly measured. However,
transthoracic echocardiography of the neonate during
paracorporeal support demonstrated some flow reversal
within the main PA, with substantial flow from the LA
cannula and some residual flow in the right and left
pulmonary veins. This suggested that most of thesupport (d) Extubated after device insertion (d) Outcome
15 Death
72 Death
NA Lung transplant
9 Weaned to medical
management
teriovenous; R, right; PPH, primary pulmonary hypertension.
ery c January 2014
TABLE 2. Demonstration of right ventricular unloading by paracorporeal lung assist device as evidenced by a decrease in pulmonary artery
pressures
Age Diagnosis Preoperative PASP* (mm Hg) Preoperative SBP (mm Hg) PASP during device supporty (mm Hg)
23 d ACD 75 50 55
2 mo AV canal, R lung hypoplasia 125 85 51
9 mo ACD 100 75 46
23 mo PPH 93 75 Not measured
PASP, Pulmonary artery systolic pressure; SBP, systemic systolic blood pressure; ACD, alveolar capillary dysplasia; AV, arteriovenous; R, right; PPH, primary pulmonary
hypertension. *As estimated using echocardiography. yPremembrane pressure plus measured cannula pressure decrease.
Hoganson et al Congenital Heart Diseaseright-sided blood flow was going through the oxygenator
circuit, with the minority of flow through the native lungs.
This was further evidenced in that the total measured blood
flow through the oxygenator was substantial given the
weight of the children. For example, the 3.3-kg neonate
had an oxygenator flow of 500 mL/min.
The relative resistance of the different cannulation
strategies used in the LA can be compared by assessingFIGURE 2. Comparison of hemodynamics of Quadrox iD oxygenator
paracorporeal support of the 2 patients with alveolar capillary dysplasia
treated with the device. A, Flow through the oxygenator. B, Mean
oxygenator inlet pressures.
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was the sum of the LA pressure and the pressure decrease
across the cannula returning the blood to the LA. Using
the 16F, right angle, metal cannula for LA return in the
23-day-old patient, the postoxygenator pressure generally
ranged from 20 to 32 mm Hg, depending on the device
flow. The conversion from a 16F, right angle, metal cannula
to the 6-mmBerlin cannula with the 10-mmGore-Tex shunt
to the LA resulted in a significant decrease in the resistance
of the outflow cannula, as evidenced by a 5-mm Hg lower
postoxygenator pressure compared with that with the 16F
cannula in the 23-day-old patient when the periods of equal
overall flow were compared.
DISCUSSION
Pediatric patients with end-stage respiratory disease who
decompensate and require ECMO have limited options if
they are unable to be weaned from ECMO within a period
of weeks. The present case series has demonstrated the
feasibility of a new treatment option for these patients. Us-
ing a paracorporeal oxygenator as a lung assist device, res-
piratory support was provided for these patients.
Ideally, this paracorporeal support should be lower risk
than ECMO and provide adequate support for these patients
for a period while they await LT. Furthermore, this approach
clearly facilitates rehabilitation, including extubation,
potential mobilization, and nutritional support of children
while awaiting LT. This was not too dissimilar to the
patients with heart failure who were rehabilitated with a
paracorporeal ventricular assist device, with resulting
positive outcomes after heart transplantation. With the
average wait time for a pediatric LT recipient of 27 days
(range, 2 to 121),9 all these patients were supported well
past the average time to LT, with the exception of the patient
who underwent LT after only 5 days of support. This
duration of support was similar to the adult experience
with Novalung and central cannulation, in which 9 patients
underwent bridged to LT, with support times of 8 to 69
days.3-5 Certainly, for some patients with decompensated
pulmonary disease, weaning from the support might be
possible, which was accomplished in 1 patient in our series.
In the 3 patients treated with the Quadrox oxygenator,
their premembrane pressures were measured continuously
postoperatively, allowing estimation of the right ventricularrdiovascular Surgery c Volume 147, Number 1 423
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pressure decrease across the cannula from the PA to
the oxygenator. These data have demonstrated a clear
unloading of the right ventricle when the patients are
receiving paracorporeal oxygenator support (Table 2). Our
previous experience in pediatric patients with heart
failure-related pulmonary hypertension treated with a
biventricular assist device showed that decompression of
the pulmonary vascular bed allows reverse remodeling
of the pulmonary vasculature.1,10 One patient with
primary pulmonary hypertension was weaned from the
paracorporeal lung assist device in the present study. It
could be postulated that right ventricular and pulmonary
vasculature unloading by the paracorporeal oxygenator
circuit contributed to the ability to wean the patient from
the device because his pulmonary vasodilators were
increased. For patients who proceed to LT, the unloading
of the right ventricle will still be beneficial and will be
optimized as cannulation strategies continue to evolve to
create a lower resistance circuit.
The safety and comfort with the paracorporeal systems
for ambulation and the extubated state might be greater
than with ECMO, just as was noted for circulatory support.
Two patients in our series were extubated for most of their
time during support; in 1 patient, respiratory failure
persisted, in part because of the less than optimal
hemodynamics. Overall, our experience was in line with
that observed in adults who received similar therapy and
were able to be extubated and participate in physical
therapy while awaiting LT. Our extubated pediatric patients
were able to interact with their families in a meaningful
way, take oral feedings, and participate in some physical
activity. The latter also resulted in substantial reductions
in the need for sedative and narcotic medications, which
could have additional implications for clinical outcomes.
Application of this technology to these patients who are
in extreme decompensation at surgery presents with
significant challenges in making the therapy available while
obtaining the right degree of approval and consent. In the
present study, each case was treated individually, with
review by the university human research protection office
and our ethics team. The institutional review board
approved our use of the Novalung. Additional application
of this therapy should include prospective institutional
review board approval, such that appropriate research data
can be collected for a careful study of this approach.
Anticoagulation management of these oxygenators in
infants was challenging because of the low flow rates and
small cardiac structures. Added to that challenge was the
metal, right angle cannula in the LA in 3 patients. The
high risk of thromboembolism led us to apply an aggressive
anticoagulation regimen, which increased the risk of
hemorrhage. Their platelet dysfunction caused by treatment
with medications with platelet inhibitory effects, such as424 The Journal of Thoracic and Cardiovascular Surgmilrinone, also increased their risk of hemorrhage. The
ATIII levels were maintained at>80%; however, that was
entirely empiric, because at that time we did not use
thromboelastography monitoring. ATIII supplementation
causing an increased heparin effect could place the patient
at additional risk of bleeding. However, with more exten-
sive monitoring, such as the use of thromboelastography,
it is possible that administration of recombinant ATII might
be beneficial if the target level of activity was maintained to
provide an optimal heparin effect in the context of adequate
clot strength. The evidence is scarce; however, 1 group
reported the infusion of ATIII during ECMO, which led to
decreased short-term bleeding complications.11 Despite
efforts to optimize the balance between bleeding or
thrombosis, strokes occurred in 3 of our 4 patients. In 1
patient, the stroke was possibly related to an unintentional
dislodgement of the circuit tubing by the patient’s legs
that occurred just before the manifestation of neurologic
symptoms. Two other patients experienced hemorrhagic
strokes that were possibly hemorrhagic conversions of
embolic strokes. Although the right angle metal cannula
in the LA approach has worked in adults with the Novalung
with minimal thrombus buildup in the LA,5 in infants and
children, this approach certainly places these patients at
risk of developing a LA thrombus. An autopsy performed
on 1 of the patients with a hemorrhagic stroke revealed a
large clot burden within the cannula and within the LA
adjacent and posterior to the metal right angle cannula.
Anticoagulation had been intermittently withheld for the
10 days before death because of the stroke, thereby
complicating the interpretation of the timing of the
development of the large LA clot burden. In the same
patient, however, the Berlin cannula was patent and without
any clot burden. The other infant who had experienced a
clinical stroke early in their treatment and had received
full anticoagulation for >50 days before their death
also had thrombus in the LA on autopsy. Finally, the
23-day-old patient had episodes of atrial dysrhythmias
that required initiation of amiodarone therapy; conceivably,
the large metal cannula contributed to irritation of the atrial
tissue and resulted in the observed rhythm disturbances.
These observations led us to adopt an alternative
approach for the fourth patient in our series, such that a
novel cannulation technique was adopted for the LA blood
return. A 10-mm Gore-Tex graft was placed in the posterior
right atrium through a small incision. The graft was
anastomosed to the perimeter of a surgically created atrial
septal defect to provide direct blood return from the circuit
to the LAwhile avoiding a foreign body projecting into the
LA (Figure 1). Although this patient was only supported for
5 days before LT, no thrombus was noted in the LA at
transplantation. This new approach may be safer, with 5
mm Hg less cannula resistance at 550 mL/min flow and
improved hemodynamics within the LA. The mainery c January 2014
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decreased risk of thrombosis, allowing less aggressive
anticoagulation and, hence, decreasing the risk of
hemorrhage.
With the PA to LA connections of the oxygenator, atrial
level shunts are not tolerated, because they can result in high
Qp/Qs flows, with a cyclical flow pattern if a left to right
atrial shunt is present. In the patient with the AV canal repair
at the transition to the paracorporeal lung assist device, a
small residual atrial level shunt was present that led to
substantial problems for the infant. In a challenging clinical
course, the patient underwent cardiac catheterization,
which demonstrated a Qp/Qs of 4:1 with high left
ventricular end-diastolic pressures owing to a slightly
unbalanced AV canal with small left-sided structures and
worsening renal function. After closure of this residual
atrial level shunt, the patient began to improve clinically
but ultimately died of multiorgan dysfunction. On the basis
of this experience, we recommend that any atrial level
shunts present in these patients should be closed during or
before transitioning to a paracorporeal lung assist device.
Additionally, patients with concomitant cardiac disease
with left-sided dysfunction might not be ideal candidates
for this type of support.
Proper guidelines for the use of this type of therapy will
come with more patient experience. On the basis of our
experience, patients with pulmonary hypertension at or
greater than the systemic pressure are potential candidates
for therapy, unless they have underlying complex
congenital heart disease or myocardial dysfunction deemed
to be irreversible or reversible within a long period
(ie, cardiomyopathy). The main question that has concerned
us has been the candidacy of patients with subsystemic
pulmonary pressures combined with severe lung disease
for this therapy. These patients depend on substantial
cardiac output through the oxygenator to provide adequate
oxygenation. Subsystemic PA pressure will facilitate
unpredictable competing native pulmonary blood flow
that could lead to marginal oxygenation. For older children,
the limited availability of the Novalung could be a barrier to
using this therapy. Other oxygenators on the market in the
United States have a pressure decrease similar to that of
the Novalung, with excellent gas transfer characteristics
that can be used for this therapy.
Potential technological developments could improve
the safety and breadth of this therapy. Decreasing the
thrombogenicity of the oxygenator and entire circuit will
be of paramount importance and could include improved
hemodynamics of the cannulas and connectors and
minimizing the circuit length and surface coatings of
the oxygenator.12-14 More substantial developments such
as microfluidic-based engineered lung devices15-18 have
potential for hemodynamically normal blood flow,
biologically active coatings, and, even, endothelializationThe Journal of Thoracic and Cato minimize the need for anticoagulation. Biologically
based therapies such as decellularized lungs that have
been recellularized19,20 might prove to be the ultimate
paracorporeal technology.
CONCLUSIONS
Paracorporeal lung assist device support of neonates and
young children has been demonstrated to be feasible in the
present early patient series. Continued optimization of
anticoagulation and additional refinement of cannulation
strategies will hopefully make this therapy applicable to
patients needing short- to medium-term lung support after
respiratory decompensation.
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Dr Mark D. Rodefeld (Indianapolis, Ind). I would like to
congratulate Dr Hoganson on a very good presentation, and I
would also like to thank you for providing me the report in
advance.
I congratulate the Washington University group for their work
in a very challenging subset of patients and for leading the way
in new therapies to treat them. In this report, Dr Hoganson has
summarized their experience with the use of paracorporeal lung
assist devices to support neonates and young children with primary
respiratory failure who are awaiting LT. Clearly, thewaiting period
for a suitable lung donor can be long, and many patients will not
survive this waiting period.
This study, which was essentially a feasibility study, with a total
of 4 patients, has shown that it is possible to successfully bridge
these patients to LT using a paracorporeal oxygenator alone.
Patients can be extubated, and this has obvious implications with
regard to quality of life.
The alternative support modality is ECMO, which has a limited
span of its own and also complicated issues of its own. In patients
with primary lung failure, ventricular or pump failure might not be
a problem, and, therefore, an oxygenator alone might be a feasible
therapy. There is no question that this is a challenging group of
patients.
I have several questions.
You might have mentioned it; I did not see it in the report, but
how many oxygenator changes were required in these patients?
Dr Hoganson. One of the patients required 2 oxygenator
changes. We did that at the bedside just by providing some
additional support and clamping the circuit, it can be done in
60 seconds. One additional oxygenator change occurred in
another patient, so 3 total. That was 1 of the real advantages
with the Quadrox—being able to monitor the pre- and postoxyge-
nator pressures. You can see sort of at the bottom of this chart that
that is actually the transoxygenator gradient, and we were able to
see whether that had increased. It is certainly a marker of potential
thrombus buildup and that was an indication to change the
oxygenator, so it was nice to have that marker for these patients.426 The Journal of Thoracic and Cardiovascular SurgDr Rodefeld. Were the devices examined for clot burden after
they were removed?
Dr Hoganson. You know, they were, and we did not see any.
Also, even at the end of this particular patient’s course when LA
thrombus was involved in that pump exchange, we fully flushed
out the thrombus. A few were present in the oxygenator, a few
specks of thrombus, but not a significant burden by any stretch,
despite withholding anticoagulation for the previous several days.
Dr Rodefeld. A significant number of strokes occurred in this
series of 4 patients. Were any of the strokes temporally related
to the oxygenator change?
Dr Hoganson. The stroke in the 23-month-old patient was
related to a bedside event when he was extubated and actually
kicked the cannula off the oxygenator and experienced a hemor-
rhagic event at the bedside. Thankfully that was immediately
stopped. He was taken to the operating room, and the device was
weaned that day. He had an embolic stroke found on imaging after
that. It is certainly a question whether hypotension precipitated the
clinical events of that stroke. That was an unusual occurrence.
The other 2 strokes we have certainly presumed were somehow
related to LA thrombus that built up as a result of the metal tip
projection into the LA.
Dr Rodefeld. So, you are more concerned about cannulation
issues as being the source of stroke?
DrHoganson.Yes, I think that was our greatest concern about a
potential etiology for the other 2 strokes.
Dr Rodefeld. It seemed as though all the patients required
ECMO support, but they had had highly variable amounts of
time from ECMO support to support by an oxygenator alone.
What were the factors influencing the decision there?
Dr Hoganson. It was mostly related to our maturation of an
understanding of when we might use this support. The first patient
received ECMO for 17 days. Obviously, once it was conceived, it
required time to get supplies in and the approval and such. The 1
patient was treated for 10 days; that was actually the second
patient. We had conceived the idea before that patient began
ECMO that perhaps we would need to use this because the
presumed diagnosis was ACD because of an older sibling who
had had it. Then, for the patient with AV canal right lung
hypoplasia, we had often discussed potentially putting this patient,
who was struggling, on this device. However, because it is a new
device, we wanted to proceed only after the patient had met the
indications for ECMO. We did not put many patients de novo on
the support. This patient was emergently given ECMO at the
bedside, and we just decided to take it down that day. It was really
an evolution as we decided who might or might not be candidates.
Dr Rodefeld. Next question. Can you foresee the possibility of
transitioning a patient directly to an oxygenator alone and not
using the intervening ECMO?
Dr Hoganson. Yes, I think so. Since this series, we have
discussed it for a couple patients. We have been struggling to
potentially avoid that other procedure and the potential for
complications. I think once we are more comfortable with which
patients will be good candidates and whowould be well supported,
we will be willing to do that.
Dr Rodefeld. ECMO obviously has its own complications and
problems that come with it, a morbidity that comes with it.
Perhaps, if a better device were available, direct conversion toery c January 2014
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Doxygenator therapy might be easier to envision, because you could
potentially avoid some of the issues that come with ECMO alone.
Also, that transitions me to my last question, which is, I know
you have done some basic work in this area. What would you
foresee as the ideal oxygenator or paracorporeal lung device? In
the best of all possible worlds, we would prefer to have a device
that we could use that has been designed expressly for passive
flow conditions. You have reported on use of a device that was
designed for use in an ECMO circuit and not expressly designed
for passive flow use.
Dr Hoganson. Right. Sometimes one is at the right place at the
right time. Also, I have done a lot of work in this area, as you
alluded, so for the past 7 years, we have been working on an
engineered lung assist device for this purpose. Also, the approach
we have been taking is an engineering approach to create
hemodynamically perfect blood flow in an engineered vasculature.
I think this, combined with using a biomaterial within the scaffold,
we will be able to have both perfect blood flow and endothelializa-
tion and thus no longer require using high-dose anticoagulation
and could use either low or no anticoagulation. I think that will
afford us a number of potential clinical options.
Certainly, the patients we have talked about today with a
paracorporeal lung assist device would be perfect candidates, in
addition to treating premature infants with premature lung disease
and umbilical cannulation directly at birth without intubating
them, potentially allowing some lung growth. Also, for older
adolescents or adults, I think potential will exist, just as others
have described, for an implantable lung assist device that could
be a bridge to LT or possibly a destination therapy after a left
ventricular assist device-type of maturation. I think really focusing
on physiologic blood flow and endothelialization in a lung device
will provide good support for these patients.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I enjoyed your
presentation. Obviously you have been treating a very challenging
group of patients. In Toronto, we have treated about 15 of these
patients with a PA-to-LA Novalung configuration. Granted most
of them were adults, but we have used this in children, down to
about 20 kg in weight. We have used a simple PA cannula and
LA cannula, either in the superior pulmonary vein or the LA
appendage, and we really have not had any stroke problems at
all. We moved to extubation, waking up, and ambulating, just as
you presented in the picture of 1 of our patients.
I wondered why you chose to use the trans-right atrial
cannulation technique with the interposition graft, the Berlin heart
cannula? That appears to complicate the situation. In the setting of
a low-flow situation, this might be a setup for stroke complications.
Dr Hoganson. Yes, I think a number of factors could have
contributed to why our reasonably small infants had issues that
your older patients did not. Certainly, 1 of the questions we were
unable to answer with these patients was how much blood flow
goes through the oxygenator and how much goes through the
native lungs. Also, echocardiography of the neonate showed
reversal of pulmonary blood flow in the pulmonary vascular and
a huge jet coming out of the cannula and a very small amountThe Journal of Thoracic and Cacoming out of the pulmonary vein. I think the overall majority
of the blood flow was coming through the oxygenator, and I think
that just set up a flow pattern sort of behind the metal tip right angle
cannula that led to some stasis, and I think that is the hemodynamic
explanation. Also, I think it was a very small atrium.
Dr del Nido. If you put a flow probe on your circuits, you
will measure what is going out across the circuit and, with a
low-resistance membrane, you can adjust that and know exactly
what is occurring.
Dr Hoganson. But the contribution of the native lungs we
were unable to state. Thus, I think that is a hemodynamic expla-
nation. Also, I think, certainly for 1 patient, they had intermittent
holding of the anticoagulation for the 10 days before death, and
perhaps that contributed to the LA thrombus in that patient. I
think that was likely. The other patient had full anticoagulation
for several weeks before the autopsy and so I do not think that
was the case. Thus, I agree. I think we certainly thought it was
going to be fine, on the basis of your work. Also, because we
had some serious clinical issues, we decided to use a different
approach.
DrKeshavjee. The point is that what is going through the native
pulmonary circulation in this patient at this point is essentially
irrelevant. If the patients are hemodynamically stable and have
flow going through the Novalung, that is what is keeping them
alive and decompressing the right side. As the pulmonary
circulation becomes better, such as in your patient who did get
better and could be weaned off, the flow in the Novalung will
decrease, so it balances itself.
Dr del Nido. Dr Keshavjee, and David for you, there is some
experience in France in treating primary pulmonary hypertension,
not in patients who are hypoxic, by creating a shunt between the
PA and the descending aorta, with some very encouraging results.
Can you comment on the potential role of this procedure.
Obviously, if you have primary lung failure or lung problems,
that is not an issue. However, for primary pulmonary hypertension,
could you comment on the role of both these techniques.
Dr Keshavjee. The issue with primary pulmonary hypertension
and the particular option we have been discussing, where you can
go PA to LA, is that you correct the physiology with your device.
You offload the right heart and provide a low vascular resistance
route to pump across.
The problem with the aorta-to-PA shunt is that it does not fix the
physiology for the lung. In those 4 or 5 cases in France, they did
have good palliation. We tried it once in a child, and it did not
work well. Within about 36 hours, we had to go back, undo the
shunt, and put a Novalung in. We got that patient through, but it
was pretty close. Thus, the PA to aorta shunt did not fix that
particular challenging patient for us. However, we did discuss it
extensively, the appeal being that if you are really worried about
whether you can successfully bridge the child to LT, it might be
better to not require a device. We have pushed, however,
toward saying we will get a lung, and we have bridged children
for 6 months on the device—that is enough time to get a lung
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